Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

A V D'Amico; R Whittington; S B Malkowicz; D Schultz; B Silver; L Henry; M Hurwitz; I Kaplan; C J Beard; J E Tomaszewski; A A Renshaw; A Wein; J P Richie

doi:10.1038/sj.pcan.4500413

Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

Prostate Cancer Prostatic Dis. 2000 Dec;3(4):259-264. doi: 10.1038/sj.pcan.4500413.

Authors

A V D'Amico¹, R Whittington, S B Malkowicz, D Schultz, B Silver, L Henry, M Hurwitz, I Kaplan, C J Beard, J E Tomaszewski, A A Renshaw, A Wein, J P Richie

Affiliation

¹ Joint Center for Radiation Therapy, Harvard Medical School, Hospital of the University of Pennsylvania.

PMID: 12497074
DOI: 10.1038/sj.pcan.4500413

Abstract

The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set. Prostate Cancer and Prostatic Diseases (2000) 3, 259-264